Paramus, New Jersey (April 24, 2024) – Throne Biotechnologies is one of the global-leading biotech companies aiming to find a cure for type 1 diabetes. We are excited to announce
We are pleased to announce that Dr. Yong Zhao collaborated with his colleagues Dr. Robert Korngold’s group at the Center For Discovery and Innovation (CDI) of Hackensack Meridian Health, published
We are happy to announce that Dr. Yong Zhao and his team published a new manuscript that revealed the new molecular mechanisms underlying Stem Cell Educator therapy for the treatment
Over the last year, Throne has made significant progresses in the FDA-approved clinical trials of Stem Cell Educator therapy for the treatment of type 1 diabetes (T1D), alopecia areata (AA)
We are pleased to announce that Dr. Yong Zhao, founder and CEO of Throne Biotechnologies, is invited by an academic journal Biomedicines to edit Special Issue, “Mitochondria in Human Health
Here at Throne Biotechnologies, we are pleased to announce Dr. Richard Fox, M.D., as our Pediatric Medical Director. Dr. Fox received his medical degree from the University of Minnesota in 1975
Type 1 diabetes (T1D) is an autoimmune disease with a shortage of islet β cells. To date, the etiology of T1D remains elusive. Increasing clinical evidence and animal studies demonstrate
Throne Biotechnologies (Throne) is a clinical-stage therapeutic company with a disruptive stem cell technology that can fundamentally reverse type 1 diabetes (T1D), alopecia areata (AA) and other autoimmune diseases through
We are happy to announce that Throne Biotechnologies (Throne) is an awardee of the “2022’s Most Promising Leaders in Biotechnologies – USA” by Corporate Vision.
We are happy to announce that Throne Biotechnologies (Throne) is one of the awardees of the “20 Admired Companies Which Everyone Should Know in 2022″ by Global Business Leaders magazine.
